Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.43 |
| ▸ | PTK6 | Q13882 | 2/20 | 0.40 |
| ▸ | TTK | P33981 | 13/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | CDK4 | P11802 | 1/20 | 0.36 |
| ▸ | CDKL1 | Q00532 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22122993 | 0.89 | TTK (0.43) | MAPKAPK5PTK6TTK | |
| SCHEMBL22123860 | 0.89 | TTK (0.43) | MAPKAPK5PTK6TTK | |
| SCHEMBL24978344 | 0.89 | TTK (0.47) | MAPKAPK5PTK6TTKSYKKCNH2 | |
| SCHEMBL30403258 | 0.82 | MAPKAPK5 (0.46) | MAPKAPK5PTK6TTKSYKAURKB | |
| SCHEMBL22154774 | 0.81 | TTK (0.43) | MAPKAPK5PTK6TTK | |
| SCHEMBL22124287 | 0.81 | TTK (0.44) | MAPKAPK5PTK6TTKKCNH2CDK4 | |
| SCHEMBL30349717 | 0.80 | TTK (0.47) | MAPKAPK5PTK6TTKSYKKCNH2 | |
| SCHEMBL30171795 | 0.79 | PTK6 (0.53) | MAPKAPK5PTK6TTKSYKAURKB | |
| SCHEMBL22124031 | 0.79 | PTK6 (0.53) | MAPKAPK5PTK6TTKSYKAURKB | |
| SCHEMBL22122954 | 0.77 | TTK (0.46) | MAPKAPK5PTK6TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230022724-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230022724-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | MAPKAPK5 728/4885PTK6 2201/4885TTK 4546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.